Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026

Santhera's H1 2026 revenue rose 101% year over year to CHF 48.3 million, while product sales increased 48% to CHF 17.2 million and operating loss narrowed to CHF 6.6 million from CHF 35.4 million. Cash increased CHF 19.4 million to CHF 41.8 million, supported by the USD 30 million Nxera licensing upfront payment, and AGAMREE sales exceeded USD 175 million on a four-quarter basis. The company maintained FY2026 revenue guidance of CHF 80-90 million and expects product sales growth above 50%, though it forecasts cash pressure in H1 2027 from inventory purchases and a mandatory German price reduction before returning to cash generation in H2 2027.

Analysis

SANN’s reported revenue acceleration is not a clean run-rate signal: upfront licensing consideration and milestone accounting flatter the income statement while cash economics remain constrained by partner royalty step-downs, milestone obligations, and the loss of North American supply revenue. The key valuation question for the next 1-3 months is whether management can demonstrate that European patient starts and China shipments replace these non-recurring components on a gross-profit basis, not merely support the maintained top-line range.

The 2027 German mandated discount is more consequential than the headline growth trajectory implies because Germany is likely the highest-margin direct market and a volume anchor for European reimbursement benchmarks. It creates a near-term cash trough precisely as inventory procurement moves forward, leaving little tolerance for delayed Italian/Spanish conversion, slower China collections, or incremental working-capital demands. Negative book equity and substantial royalty-purchase/term-loan obligations also mean equity remains highly sensitive to a modest revision in the path to self-funding, despite management’s no-financing assertion.

The underappreciated positive is strategic: broader real-world evidence could shift treatment persistence and expand use beyond the core ambulatory pediatric population, increasing lifetime value rather than simply new-patient incidence. That opportunity is not yet investable from a small retrospective cohort; the investable confirmation would be sustained refill/persistence metrics and prospective GUARDIAN data. For CPRX/Angelini, AGAMREE is now strategically relevant to rare-disease scale, but its direct public-market read-through is limited following the acquisition.

Consensus may overreact positively to four-quarter global sales thresholds without recognizing that each threshold can generate sizable pass-through milestone costs, temporarily muting incremental operating leverage. Conversely, a German price reset is likely a known de-risking event rather than evidence of demand impairment if unit growth remains above price erosion; distinguishing volume from net-price realization at the next update is essential.

Key Decisions for Investors

• Maintain SANN as a tactical long/watch position only after the analyst call confirms 2026 product-sales guidance, German net-price impact, and cash at 30 September. Target a 1-3 month rerating on evidence that Italy and Spain are converting to paid demand; exit on reduced product-sales growth guidance or any indication that H1 2027 liquidity requires external capital.
• Do not annualize H1 margins or apply a revenue multiple to total reported revenue. Underwrite SANN on recurring direct product sales plus royalty streams, haircutting licensing milestones to zero; this avoids paying for non-repeatable revenue and milestone-funded cash generation.
• Set a Q4 monitoring trigger for SANN: paid launch uptake in Italy/Spain, China shipment-to-collection conversion, and explicit German discount magnitude. If aggregate direct-market unit growth falls below the level needed to offset German net-price pressure, move to short/avoid rather than add on apparent top-line growth.
• Treat any CPRX exposure as no longer a clean vehicle for AGAMREE upside; assess Angelini’s execution privately rather than using legacy CPRX fundamentals as a read-through. The more relevant liquid proxy is SANN, but position sizing should reflect Swiss small-cap liquidity and balance-sheet convexity.